Wu, Ming-Fang
Lin, Chih-An
Yuan, Tzu-Hang
Yeh, Hsiang-Yuan
Su, Sheng-Fang
Guo, Chin-Lin
Chang, Gee-Chen
Li, Ker-Chau
Ho, Chao-Chi
Chen, Huei-Wen http://orcid.org/0000-0001-5051-9896
Funding for this research was provided by:
Ministry of Science and Technology, Taiwan (107-2627-M-002-001-, 107-2314-B-002-244-MY3, 108-2321-B-038-003, 108-3114-Y-001-002)
Academia Sinica (AS-SUMMIT-108)
Article History
Received: 11 December 2019
Accepted: 22 October 2020
First Online: 11 November 2020
Compliance with ethical standards
:
: Dr. Ho has received grants from AstraZeneca (#ISSIRES0105) and has received honorarium for speeches or participated in compensated advisory boards of Boehringer Ingelheim, Eli Lilly, Roche/Genentech/Chugai, MSD, Pfizer, Novartis, BMS and Ono pharmaceutical. The remaining authors declare no conflicts of interest.
: All experiments were based on the institutional review board (IRB) protocol of the NTUH Research Ethics Committee (IRB approval number: 200709004R and 201604086RINA).
: MPEs were collected from 147 lung cancer patients with stage IV adenocarcinoma at National Taiwan University Hospital (NTUH) from 2008 to 2020. Written informed consent was collected from all subjects.